Oncology Xagena
High copy number of the epidermal growth factor receptor ( EGFR ) may be an effective predictor of Gefitinib ( Iressa ) efficacy in non-small-cell lung cancer. Gefitinib is a selective inhibitor o ...
AstraZeneca announced that after discussions with the FDA ( U.S. Food and Drug Administration ), the company is making a labeling change to Iressa ( Gefitinib ). Based on the FDA's assessment of cu ...
Researchers at Cedars-Sinai Medical Center have identified a protein called EMP-1 that is present in the tumors of patients who fail to respond to treatment with Gefitinib ( Iressa ), a drug used in t ...
Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective ...
Patients with the most common form of lung cancer, non-small-cell lung cancer, who have mutations in the epidermal growth factor receptor ( EGFR ) gene have significantly improved progression-free sur ...
Colorectal cancer is one of the most common human malignancies with greater than 300,000 cases both in the United States and in the European Union each year. In the past decade, survival of metastat ...
Improved disease control with continuation of EGFR inhibition beyond progression has been suggested in retrospective / non-randomized studies, however, this has yet to be prospectively evaluated in a ...
LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive care in comparison with placebo and best supportive care, as a third-line or fourth-line the ...
A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...
First-line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) is standard of care for patients with EGFR-mutated non-small-cell lung cancer ( NSCLC ). The EGFR TKI Osimertinib ( Tagrisso ) is ...
Osimertinib ( Tagrisso ) is a 3rd-generation, CNS-active, epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI ) [ EGFR-TKI ] with superior efficacy to comparator EGFR-TKI ( Gefit ...
